Showing results (31-40 of 47) with videos related to
Sort By:
Pageof 5
Journal of Clinical Pharmacology|March 22, 2005
Safety, tolerability, and pharmacokinetics of a capsule formulation of DRF-1042, a novel camptothecin analog, in refractory cancer patients in a bridging phase I studyArani Chatterjee, Raghunadharao Digumarti, Kasiram Katneni, et al.Journal of Clinical Pharmacology|June 17, 2004
Safety, tolerability, pharmacokinetics, and pharmacodynamics of an orally active novel camptothecin analog, DRF-1042, in refractory cancer patients in a phase I dose escalation studyArani Chatterjee, Raghunadharao Digumarti, Rao N V S Mamidi, et al.Indian Journal of Medical and Paediatric Oncology : Official Journal of Indian Society of Medical & Paediatric Oncology|March 8, 2014
Histopathological pattern of lymphomas and clinical presentation and outcomes of diffuse large B cell lymphoma: A multicenter registry based study from IndiaRamesh B V Nimmagadda, Raghunadharao Digumarti, Reena Nair, et al.The Oncologist|December 11, 2013
Barriers and challenges to global clinical cancer researchBostjan Seruga, Aleksander Sadikov, Eduardo L Cazap, et al.Indian Journal of Palliative Care|September 13, 2021
Organising Home-based Palliative Care Services: A Quality Improvement project at the Homi Bhabha Cancer Hospital and Research Centre, VishakhapatnamVidya Viswanath, Leela Digumarti, Nadimpalli Satyanarayana Raju, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 5, 2011
Randomized, double-blind, placebo-controlled phase II study of single-agent oral talactoferrin in patients with locally advanced or metastatic non-small-cell lung cancer that progressed after chemotherapyPurvish M Parikh, Ashok Vaid, Suresh H Advani, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 3, 2011
A randomized, double-blind, placebo-controlled, phase II study of oral talactoferrin in combination with carboplatin and paclitaxel in previously untreated locally advanced or metastatic non-small cell lung cancerRaghunadharao Digumarti, Yenyun Wang, Ganapathi Raman, et al.European Journal of Cancer (Oxford, England : 1990)|July 30, 2013
Three-arm randomised controlled phase 2 study comparing pemetrexed and erlotinib to either pemetrexed or erlotinib alone as second-line treatment for never-smokers with non-squamous non-small cell lung cancerDae Ho Lee, Jung Shin Lee, Sang-We Kim, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 2, 2008
Clinical experience with gefitinib in Indian patientsPurvish Parikh, Alex Yuang-Chi Chang, Shona Nag, et al.The Lancet. Oncology|June 2, 2012
Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: a phase 3, multicentre, open-label, randomised trialRuth Pettengell, Bertrand Coiffier, Geetha Narayanan, et al.Pageof 5